JP2014505877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505877A5 JP2014505877A5 JP2013549812A JP2013549812A JP2014505877A5 JP 2014505877 A5 JP2014505877 A5 JP 2014505877A5 JP 2013549812 A JP2013549812 A JP 2013549812A JP 2013549812 A JP2013549812 A JP 2013549812A JP 2014505877 A5 JP2014505877 A5 JP 2014505877A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- bubr1
- level
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11151677.9 | 2011-01-21 | ||
| EP11151677 | 2011-01-21 | ||
| PCT/EP2012/050818 WO2012098207A1 (en) | 2011-01-21 | 2012-01-19 | Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014505877A JP2014505877A (ja) | 2014-03-06 |
| JP2014505877A5 true JP2014505877A5 (https=) | 2015-03-12 |
| JP6302673B2 JP6302673B2 (ja) | 2018-03-28 |
Family
ID=43920866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549812A Expired - Fee Related JP6302673B2 (ja) | 2011-01-21 | 2012-01-19 | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのｂｕｂｒ１の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10222377B2 (https=) |
| EP (1) | EP2666016B1 (https=) |
| JP (1) | JP6302673B2 (https=) |
| CN (1) | CN103314295B (https=) |
| AU (1) | AU2012208520B2 (https=) |
| CA (2) | CA2822491C (https=) |
| DK (1) | DK2666016T3 (https=) |
| ES (1) | ES2620582T3 (https=) |
| HU (1) | HUE032643T2 (https=) |
| PL (1) | PL2666016T3 (https=) |
| PT (1) | PT2666016T (https=) |
| WO (1) | WO2012098207A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10006078B2 (en) * | 2011-03-29 | 2018-06-26 | Basilea Pharmaceutica Ag | Use of phospho-Akt as a biomarker of drug response |
| WO2015173341A1 (en) * | 2014-05-13 | 2015-11-19 | Basilea Pharmaceutica Ag | Dosage principle for anti-cancer furazanylbenzimidazoles |
| EP3365680A1 (en) | 2015-10-22 | 2018-08-29 | Basilea Pharmaceutica International AG | Use of eb1 as a biomarker of drug response |
| MX388196B (es) | 2017-04-26 | 2025-03-19 | Basilea Pharm Int Ag | Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos. |
| WO2018210868A1 (en) | 2017-05-16 | 2018-11-22 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
| CN107119137B (zh) * | 2017-05-26 | 2018-04-06 | 广州华弘生物科技有限公司 | 一种快速检测HER‑2/neu基因表达的检测试剂盒 |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998056910A1 (en) | 1997-06-11 | 1998-12-17 | Chiron Corporation | DETECTION OF LOSS OF THE WILD-TYPE huBUB1 GENE |
| US6593098B1 (en) | 1997-12-01 | 2003-07-15 | Fox Chase Cancer Center | Genes encoding proteins involved in mitotic checkpoint control and methods of use thereof |
| KR100876327B1 (ko) * | 2001-02-21 | 2008-12-31 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 진단에서의, 그리고 암에서 치료 표적으로서의 ｔｔｋ |
| MXPA05006920A (es) * | 2002-12-24 | 2006-02-10 | Astrazeneca Ab | Compuestos de quinazolina. |
| DK1636215T3 (da) * | 2003-05-23 | 2008-06-02 | Basilea Pharmaceutica Ag | Furazanobenzimidazoler |
| US8021831B2 (en) * | 2003-08-25 | 2011-09-20 | Board Of Regents, The University Of Texas System | Taxane chemosensitivity prediction test |
| US20050136177A1 (en) | 2003-08-25 | 2005-06-23 | Anthony Hesse | Method for coloring landscaping materials using foamable dry colorant |
| CN102747140A (zh) * | 2004-12-08 | 2012-10-24 | 安万特药物公司 | 测量对多西他赛抗药性或敏感性的方法 |
| JP2009173629A (ja) * | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体 |
| EA020703B9 (ru) * | 2008-06-26 | 2015-12-30 | Ле Лаборатуар Сервье | Пиразолохиназолины |
| NZ597376A (en) | 2009-07-27 | 2014-01-31 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
-
2012
- 2012-01-19 CA CA2822491A patent/CA2822491C/en active Active
- 2012-01-19 US US13/980,180 patent/US10222377B2/en active Active
- 2012-01-19 AU AU2012208520A patent/AU2012208520B2/en not_active Ceased
- 2012-01-19 PL PL12701341T patent/PL2666016T3/pl unknown
- 2012-01-19 WO PCT/EP2012/050818 patent/WO2012098207A1/en not_active Ceased
- 2012-01-19 CN CN201280005583.6A patent/CN103314295B/zh not_active Expired - Fee Related
- 2012-01-19 ES ES12701341.5T patent/ES2620582T3/es active Active
- 2012-01-19 JP JP2013549812A patent/JP6302673B2/ja not_active Expired - Fee Related
- 2012-01-19 EP EP12701341.5A patent/EP2666016B1/en active Active
- 2012-01-19 HU HUE12701341A patent/HUE032643T2/en unknown
- 2012-01-19 PT PT127013415T patent/PT2666016T/pt unknown
- 2012-01-19 DK DK12701341.5T patent/DK2666016T3/en active
- 2012-01-19 CA CA3142576A patent/CA3142576A1/en active Pending
-
2016
- 2016-03-04 US US15/060,998 patent/US9970938B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505877A5 (https=) | ||
| Borger et al. | Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma | |
| Takegawa et al. | HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy | |
| JP2019510066A5 (https=) | ||
| Rayson et al. | Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer | |
| EA200702203A1 (ru) | Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений | |
| BRPI0922779A8 (pt) | complexos de tecnécio e rênio-bis(heteroarila) e métodos de uso dos mesmos para inibir psma | |
| MY156210A (en) | Compounds and methods for kinase modulation, and indications therefor | |
| MY209048A (en) | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases | |
| JP2017121233A5 (https=) | ||
| JP2009536620A5 (https=) | ||
| RU2015115151A (ru) | Ингибитор ret | |
| JP2011504462A5 (https=) | ||
| BR112015029318A2 (pt) | marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável | |
| EA200901611A1 (ru) | Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей | |
| JP2013520681A5 (https=) | ||
| RU2017120287A (ru) | ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43 | |
| Hu et al. | Aberrant expression of Notch3 predicts poor survival for hepatocellular carcinomas | |
| MX2017015210A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
| JP2019515643A5 (https=) | ||
| JP2014533960A5 (https=) | ||
| JP2023508996A (ja) | Ｃｄｋ１２／１３阻害剤を用いる癌の処置 | |
| RU2015138688A (ru) | Маркеры, ассоциированные с ингибиторами wnt | |
| Gockel et al. | Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer | |
| Breunig et al. | BRaf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma |